Skip to main content
×
×
Home

Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma

  • Neil C. Williams (a1), Kirsty A. Hunter (a1), Dominick E. Shaw (a2), Kim G. Jackson (a3), Graham R. Sharpe (a1) and Michael A. Johnson (a1)...
Abstract

Although high dose n-3 PUFA supplementation reduces exercise- and hyperpnoea-induced bronchoconstriction (EIB/HIB), there are concurrent issues with cost, compliance and gastrointestinal discomfort. It is thus pertinent to establish the efficacy of lower n-3 PUFA doses. Eight male adults with asthma and HIB and eight controls without asthma were randomly supplemented with two n-3 PUFA doses (6·2 g/d (3·7 g EPA and 2·5 g DHA) and 3·1 g/d (1·8 g EPA and 1·3 g DHA)) and a placebo, each for 21 d followed by 14 d washout. A eucapnic voluntary hyperpnoea (EVH) challenge was performed before and after treatments. Outcome measures remained unchanged in the control group. In the HIB group, the peak fall in forced expiratory volume in 1 s (FEV1) after EVH at day 0 (−1005 (sd 520) ml, −30 (sd 18) %) was unchanged after placebo. The peak fall in FEV1 was similarly reduced from day 0 to day 21 of 6·2 g/d n-3 PUFA (−1000 (sd 460) ml, −29 (sd 17) % v. −690 (sd 460) ml, −20 (sd 15) %) and 3·1 g/d n-3 PUFA (−970 (sd 480) ml, −28 (sd 18) % v. −700 (sd 420) ml, −21 (sd 15) %) (P<0·001). Baseline fraction of exhaled nitric oxide was reduced by 24 % (P=0·020) and 31 % (P=0·018) after 6·2 and 3·1 g/d n-3 PUFA, respectively. Peak increases in 9α, 11β PGF2 after EVH were reduced by 65 % (P=0·009) and 56 % (P=0·041) after 6·2 and 3·1 g/d n-3 PUFA, respectively. In conclusion, 3·1 g/d n-3 PUFA supplementation attenuated HIB and markers of airway inflammation to a similar extent as a higher dose. Lower doses of n-3 PUFA thus represent a potentially beneficial adjunct treatment for adults with asthma and EIB.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma
      Available formats
      ×
Copyright
Corresponding author
* Corresponding author: Dr N. C. Williams, email neil.williams@ntu.ac.uk
References
Hide All
1. Carlsen, K, Anderson, S, Bjermer, L, et al. (2008) Exercise‐induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy 63, 387403.
2. Weiler, JM, Anderson, SD, Randolph, C, et al. (2010) Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. Ann Allergy Asthma Immunol 105, S1S47.
3. Hallstrand, TS (2012) New insights into pathogenesis of exercise-induced bronchoconstriction. Curr Opin Allergy Clin Immunol 12, 4248.
4. Hallstrand, TS, Altemeier, WA, Aitken, ML, et al. (2013) Role of cells and mediators in exercise-induced bronchoconstriction. Immunol Allergy Clin North Am 33, 313328.
5. Barnes, PJ (2010) New therapies for asthma: is there any progress? Trends Pharmacol Sci 31, 335343.
6. Ramage, L, Lipworth, B, Ingram, C, et al. (1994) Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 88, 363368.
7. Kumar, A, Mastana, SS & Lindley, MR (2016) n-3 Fatty acids and asthma. Nutr Research Rev 29, 116.
8. Calder, PC (2010) Omega-3 fatty acids and inflammatory processes. Nutrients 2, 355374.
9. Arm, JP, Horton, CE, Mencia-Huerta, JM, et al. (1988) Effect of dietary supplementation with fish oil lipids on mild asthma. Thorax 43, 8492.
10. Mickleborough, TD, Murray, RL, Ionescu, AA, et al. (2003) Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med 168, 11811189.
11. Mickleborough, TD, Lindley, MR, Ionescu, AA, et al. (2006) Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma. Chest 129, 3949.
12. Brannan, JD, Bood, J, Alkhabaz, A, et al. (2015) The effect of omega-3 fatty acids on bronchial hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma. Chest 147, 397405.
13. Reisman, J, Schachter, H, Dales, R, et al. (2006) Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review. BMC complement Altern Med 6, 1.
14. Weiler, JM, Brannan, JD, Randolph, CC, et al. (2016) Exercise-induced bronchoconstriction update – 2016. J Allergy Clin Immunol 138, 12921295. e36.
15. Kumar, A, Mastana, SS & Lindley, MR (2016) EPA/DHA dietary supplementation attenuates exercise-induced bronchoconstriction in physically active asthmatic males. Cogent Med 3, 1172696.
16. Mickleborough, T & Lindley, M (2014) The effect of combining fish oil and vitamin C on airway inflammation and hyperpnea-induced bronchoconstriction in asthma. J Allergy Ther 5, 2.
17. Tecklenburg-Lund, S, Mickleborough, TD, Turner, LA, et al. (2010) Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction. PLoS ONE 5, e13487.
18. Price, OJ, Hull, JH, Howatson, G, et al. (2015) Vitamin D and omega-3 polyunsaturated fatty acid supplementation in athletes with exercise-induced bronchoconstriction: a pilot study. Expert Rev Respir Med 9, 369378.
19. Burns, CP, Halabi, S, Clamon, G, et al. (2004) Phase II study of high‐dose fish oil capsules for patients with cancer‐related cachexia. Cancer 101, 370378.
20. Walser, B & Stebbins, CL (2008) Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise. Eur J Appl Physiol 104, 455461.
21. Williams, NC, Johnson, MA, Hunter, KA, et al. (2015) Reproducibility of the bronchoconstrictive response to eucapnic voluntary hyperpnoea. Respir Med 109, 12621267.
22. Williams, N, Hunter, K, Johnson, M, et al. (2013) A randomised placebo controlled trial to compare the effects of two dosages of omega-3 PUFA on exercise-induced bronchoconstriction (EIB). Br J Sports Med 47, e4e4.
23. Argyros, GJ, Roach, JM, Hurwitz, KM, et al. (1996) Eucapnic voluntary hyperventilation as a bronchoprovocation technique: development of a standardized dosing schedule in asthmatics. Chest 109, 15201524.
24. Anderson, SD, Argyros, GJ, Magnussen, H, et al. (2001) Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. Br J Sports Med 35, 344347.
25. Parsons, JP, Hallstrand, TS, Mastronarde, JG, et al. (2013) An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med 187, 10161027.
26. Boulet, LP, FitzGerald, JM & Reddel, HK (2015) The revised 2014 GINA strategy report: opportunities for change. Curr Opin Pulm Med 21, 17.
27. Duffy, P & Phillips, Y (1991) Caffeine consumption decreases the response to bronchoprovocation challenge with dry gas hyperventilation. Chest 99, 13741377.
28. Vally, H & Thompson, P (2002) Alcoholic drinks and asthma. Clin Exp Allergy 32, 186191.
29. Yusof, HM, Miles, EA & Calder, P (2008) Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids 78, 219228.
30. Bahal, SM, Romansky, JM & Alvarez, FJ (2003) Medium chain triglycerides as vehicle for palatable oral liquids: TECHNICAL NOTE. Pharm Dev Technol 8, 111115.
31. Miller, MR, Hankinson, J, Brusasco, V, et al. (2005) Standardisation of spirometry. Eur Respir J 26, 319338.
32. Dweik, RA, Boggs, PB, Erzurum, SC, et al. (2011) An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184, 602615.
33. Alving, K, Weitzberg, E & Lundberg, JM (1993) Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 6, 13681370.
34. Junge, W, Wilke, B, Halabi, A, et al. (2004) Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 344, 137148.
35. Nauseef, WM (2007) Isolation of human neutrophils from venous blood. Methods Mol Biol, 412, 1520.
36. Bligh, EG & Dyer, WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37, 911917.
37. Jackson, KG, Bateman, PA, Yaqoob, P, et al. (2009) Impact of saturated, polyunsaturated and monounsaturated fatty acid-rich micelles on lipoprotein synthesis and secretion in Caco-2 cells. Lipids 44, 10811089.
38. Santanello, N, Zhang, J, Seidenberg, B, et al. (1999) What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 14, 2327.
39. Williams, NC, Johnson, MA, Shaw, DE, et al. (2016) A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation. Br J Nutr 116, 798804.
40. Reiss, TF, Hill, JB, Harman, E, et al. (1997) Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 52, 10301035.
41. Shapiro, GG, Kemp, JP, DeJong, R, et al. (1990) Effects of albuterol and procaterol on exercise-induced asthma. Ann Allergy 65, 273276.
42. Nelson, JA, Strauss, L, Skowronski, M, et al. (1998) Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 339, 141146.
43. Anderson, S, Rodwell, L, Du Toit, J, et al. (1991) Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 100, 12541260.
44. Bronsky, EA, Yegen, Ü, Yeh, CM, et al. (2002) Formoterol provides long-lasting protection against exercise-induced bronchospasm. Ann Allergy Asthma Immunol 89, 407412.
45. Cheung, D, Timmers, MC, Zwinderman, AH, et al. (1992) Long-term effects of a long-acting β2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 327, 11981203.
46. Simons, FE, Gerstner, TV & Cheang, MS (1997) Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 99, 655659.
47. Mickleborough, T & Rundell, K (2005) Dietary polyunsaturated fatty acids in asthma-and exercise-induced bronchoconstriction. Eur J Clin Nutr 59, 13351346.
48. Brannan, JD & Lougheed, MD (2012) Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment. Front Physiol 3, 460.
49. O’Sullivan, S, Roquet, A, Dahlen, B, et al. (1998) Evidence for mast cell activation during exercise-induced bronchoconstriction. Eur Respir J 12, 345350.
50. Brannan, JD, Gulliksson, M, Anderson, SD, et al. (2003) Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur Respir J 22, 491496.
51. Daviskas, E, Anderson, SD, Brannan, JD, et al. (1997) Inhalation of dry-powder mannitol increases mucociliary clearance. Eur Respir J 10, 24492454.
52. Daviskas, E, Anderson, SD, Gonda, I, et al. (1995) Changes in mucociliary clearance during and after isocapnic hyperventilation in asthmatic and healthy subjects. Eur Respir J 8, 742751.
53. Kippelen, P, Fitch, KD, Anderson, SD, et al. (2012) Respiratory health of elite athletes – preventing airway injury: a critical review. Br J Sports Med 46, 471476.
54. Kippelen, P, Tufvesson, E, Ali, L, et al. (2013) Urinary CC16 after challenge with dry air hyperpnoea and mannitol in recreational summer athletes. Respir Med 107, 18371844.
55. Romberg, K, Bjermer, L & Tufvesson, E (2011) Exercise but not mannitol provocation increases urinary Clara cell protein (CC16) in elite swimmers. Respir Med 105, 3136.
56. Mickleborough, TD, Vaughn, CL, Shei, R, et al. (2013) Marine lipid fraction PCSO-524™(lyprinol®/omega XL®) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma. Respir Med 107, 11521163.
57. Simpson, AJ, Bood, JR, Anderson, SD, et al. (2016) A standard, single dose of inhaled terbutaline attenuates hyperpnea-induced bronchoconstriction and mast cell activation in athletes. J Appl Physiol (1985) 120, 10111017.
58. Schubert, R, Kitz, R, Beermann, C, et al. (2009) Effect of n-3 polyunsaturated fatty acids in asthma after low-dose allergen challenge. Int Arch Allergy Immunol 148, 321329.
59. Hamid, Q, Springall, DR, Polak, J, et al. (1993) Induction of nitric oxide synthase in asthma. Lancet 342, 15101513.
60. Robbins, R, Springall, D, Warren, J, et al. (1994) Inducible nitric oxide synthase is increased in murine lung epithelial cells by cytokine stimulation. Biochem Biophys Res Commun 198, 835843.
61. Barnes, PJ (1995) Nitric oxide and airway disease. Ann Med 27, 389393.
62. Schmitz, G & Ecker, J (2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47, 147155.
63. Accordino, R, Visentin, A, Bordin, A, et al. (2008) Long-term repeatability of exhaled breath condensate pH in asthma. Respir Med 102, 377381.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed